Informed consent in a clinical trial is the process by which a study explains its purpose, procedures, risks, benefits, and alternatives to a prospective participant clearly enough that the person can agree to enroll without pressure or confusion. The FDA and the Office for Human Research Protections (OHRP) both require it before enrollment, and an Institutional Review Board (IRB) has to approve the exact wording before a recruitment campaign can point anyone toward it.
When you look online for for an informed consent example, you'll mostly find downloadable templates: fillable .doc files from a university research office or a federal agency, with blanks for study-specific details. While these templates show the required sections, they don't show why one phrasing choice clears IRB review while a similar sentence gets sent back, or how a recruitment ad's promises have to line up with what the consent form actually says. This guide breaks down three annotated, composite consent sections, each paired with a plain-language rewrite and specific notes on what makes the language work.
Consent Is the Conversion Point of the Enrollment Funnel
Consent is the single point in a clinical trial's enrollment funnel where a qualified, motivated candidate can still walk away, and it is the point most recruitment strategies stop measuring. A candidate who clicked a Google or Meta ad, called the site, passed a phone screen, and showed up for a baseline visit has already cleared every marketing and operational filter a sponsor built into the funnel. The consent conversation is the last filter, and it belongs to the study team, not the media plan.
The pace data showing how far enrollment funnels slip accounts for this gap . Sites that treat consent as a compliance checkbox instead of the funnel's final conversion event see strong screen-to-consent numbers on paper and weak consent-to-randomization numbers in practice. The recruitment materials that got a candidate to the consent conversation set an expectation. If the consent form's actual risk, benefit, and time-commitment language doesn't match that expectation, the candidate notices the gap in the room, not in a dashboard, and the study loses an enrollment it already paid to generate.
What Informed Consent Actually Requires
Informed consent for a clinical trial has to satisfy two overlapping federal standards: the FDA's basic elements of consent under 21 CFR 50.25, and the Common Rule's general requirements under the Office for Human Research Protections' 45 CFR 46.116. Both apply whenever a trial involves FDA-regulated products or federally funded human-subjects research, which covers the large majority of sponsored trials recruiting in the US.
21 CFR 50.25 lists the basic elements every consent form has to include: a statement that the study involves research, its purposes, and the expected duration; a description of the procedures and which ones are experimental; a description of reasonably foreseeable risks and discomforts; a description of any expected benefits; disclosure of appropriate alternative treatments; a statement about confidentiality of records; for research involving more than minimal risk, an explanation of compensation and treatment if injury occurs; contact information for questions about the research and about research-related injuries; and a statement that participation is voluntary and can be withdrawn at any time without penalty.
45 CFR 46.116 layers on the general requirements: consent has to be sought under circumstances that minimize the possibility of coercion or undue influence, in language understandable to the subject, and it has to avoid exculpatory language that waives or appears to waive any of the subject's legal rights. An IRB reviews the form against both standards before recruitment materials referencing the study can go live.
The Four Principles Behind Every Compliant Consent Form
Every compliant consent form rests on four principles that FDA and OHRP regulations both build into their requirements: voluntariness, comprehension, disclosure, and decision-making capacity, drawn directly from 21 CFR 50.25 and 45 CFR 46.116. Voluntariness means the decision to enroll can't be shaped by pressure from a physician, a payment structure, or a recruitment ad's urgency language, which is why compliant forms separate the compensation section from the benefits section instead of blending them into one persuasive pitch.
Comprehension means the participant actually understands what they read, not just that they were handed the right document, which is why plain-language phrasing replaces clinical jargon like "randomization" or "placebo-controlled" rather than pairing the jargon with a gloss. Disclosure means every material fact a reasonable person would want before deciding appears in the form, including facts that make the study look less appealing, which is why a well-drafted risks section names specific adverse events observed in earlier phases rather than a generic "you may experience side effects" line.
Decision-making capacity means the person signing has to be legally and cognitively able to consent for themselves, which is why a consent process includes a capacity check for populations where impairment is plausible, such as certain neurological or psychiatric trials, before the form is ever presented. Each principle shows up as a specific drafting choice, not an abstract ideal the form gestures at.
What This Guide Is (and Isn't)
This guide provides educational guidance for writing recruitment-compliant, research consent materials; it is not legal advice. It explains why specific phrasing choices clear IRB review under FDA and OHRP standards, but it is not a substitute for review by the study's own IRB and legal counsel. Every example in this guide is composite and illustrative, modeled on the structure of public federal templates, never a ready-to-use form. Final consent language always has to clear your institution's own review process before it reaches a participant.
Annotated Example: The Purpose and Procedures Section
The purpose and procedures section is where a compliant form and a marketing headline diverge most, since 21 CFR 50.25 and the study's IRB both require the treatment's actual evidentiary status, not just its promise, to appear in the first paragraph. Composite example, modeled on the structure of federal templates including the NIA informed consent template:
"You are being asked to take part in a research study to find out whether Drug X, taken once daily, reduces joint pain in adults with moderate osteoarthritis better than the current standard treatment. This study is being done because earlier, smaller studies suggested a benefit, but it has not yet been proven in a study of this size. If you agree to take part, you will visit the clinic six times over 12 weeks. At each visit, study staff will ask about your pain level, check your blood pressure, and draw a small blood sample. You will be randomly assigned, like a coin flip, to receive either Drug X or the current standard treatment. Neither you nor the study staff will know which one you are receiving until the study ends."
Plain-language rewrite for a recruitment landing page or intake call script:
"This study is testing whether a new daily pill works better than the current treatment for joint pain. If you join, you'll come in six times over three months for checkups and a blood draw. You won't know which treatment you're getting, and neither will the study team, until the study is over."
Three phrasing choices make the original compliant rather than promotional. First, "suggested a benefit, but it has not yet been proven" states the study's actual evidentiary status instead of implying the drug already works, a distinction 21 CFR 50.25 requires and a recruitment ad frequently blurs. Second, "like a coin flip" explains randomization through a comprehension-level analogy instead of the clinical term alone. Third, stating the visit count and duration as facts in the purpose section itself, rather than deferring them to a separate document, discloses the time commitment before the participant reaches the risks section.
Annotated Example: Risks, Benefits, and Alternatives
The risks, benefits, and alternatives section is where recruitment copy most often overpromises, because IRBs apply 21 CFR 50.25's benefit-disclosure standard literally: individual benefit has to be described as possible, never promised. Composite example, modeled on the risk-disclosure structure used in FDA's informed consent template for expanded access:
"Possible side effects of Drug X seen in earlier studies include nausea (reported by about 18 percent of participants), headache (12 percent), and elevated liver enzymes (4 percent), which resolved after stopping the drug in all reported cases. There is also a risk of side effects that are not yet known, since Drug X has not been used in as many people as an approved treatment. You may or may not experience any personal benefit from taking part in this study; joint pain may improve, stay the same, or in rare cases worsen. The main alternative to joining this study is continuing your current treatment as prescribed by your own doctor, which carries its own established risks and benefits that your doctor can explain. You may also choose not to participate at all, with no effect on your current medical care."
Plain-language rewrite:
"Some people in earlier studies had nausea, headaches, or changes in liver function; most went away after stopping the drug. Because this drug is still being studied, there could be side effects we don't know about yet. Joining might help your joint pain, might not change it, or in rare cases might make it worse. You can also stick with your current treatment instead, or choose not to join at all, and either choice will not affect the care you already get."
Most recruitment teams get one callout wrong: the sentence "you may or may not experience any personal benefit" has to survive into the plain-language rewrite in some form, because 21 CFR 50.25 requires expected benefits to be disclosed honestly, not implied as certain. A recruitment ad that promises relief, results, or improvement without that same uncertainty attached is making a claim the consent form is not permitted to make.
Annotated Example: Compensation and Costs Language
Compensation and cost disclosure has one job under 45 CFR 46.116: state the payment and cost facts without turning them into the study's selling point, the same way an IRB evaluates a compensation section separately from the benefits section. Composite example:
"You will be paid $50 for each completed study visit, up to a maximum of $300 for all six visits, to compensate you for your time and travel. Payment will be made regardless of whether you complete the entire study; if you withdraw after visit two, you will be paid for the two visits you completed. There is no cost to you for the study drug, study-related visits, or study-related lab tests. Your health insurance may still be billed for any care you receive that is not part of the study protocol, such as treatment for a condition unrelated to this research."
Plain-language rewrite:
"You'll be paid $50 per visit, up to $300 total if you complete all six visits, for your time and travel. You still get paid for the visits you finish even if you decide to stop early. The study drug, visits, and lab tests are free to you; your regular insurance may be billed for anything outside the study itself."
The version that fails IRB review usually looks like this instead: "Get paid up to $300 for participating in this exciting new study!" That phrasing frames payment as a reward for enrolling rather than compensation for time and burden, the distinction 45 CFR 46.116 and most IRB policies draw explicitly. That framing reads as coercive, especially for lower-income candidates, for whom the amount could function as undue influence rather than fair reimbursement. The compliant version states the dollar amount once, ties it to a specific unit (per visit), and never uses exclamation points or urgency language anywhere near the payment figure.
Where Recruitment Marketing Claims Cross the Line Into Consent Violations
Recruitment marketing for a clinical trial crosses into consent-violation territory in three predictable ways: overstating benefit certainty, downplaying risk, and framing payment as a reward. FDA's 21 CFR 50.25 basic elements are the standard each of those violations breaks. A landing page headline that reads "New treatment shows promise for joint pain relief" is defensible if the underlying data shows promise; a headline that reads "Get relief from joint pain" implies a guaranteed outcome the consent form itself is not permitted to promise, since the FDA's basic elements require disclosing that individual benefit is uncertain.
The same gap shows up with risk. An ad can fail in two ways: it lists a condition's symptoms and a drug's mechanism but omits any mention that the treatment is investigational, or it buries a serious adverse event behind a generic "side effects may occur" line. Either version sets an expectation the consent form then has to walk back in a room with a coordinator, which is where candidates disengage.
Recruitment copy that promises more than a trial can deliver gets flagged fast, since Google and Meta both route health-condition ads through the platform review a recruitment ad has to pass before it ever runs. But platform review catches obvious violations, not subtle ones. A phrase like "earn $300" passes most platform ad reviews without issue while still failing the compensation-as-reward standard IRBs apply to the consent form itself. The fix isn't softer marketing copy; it's marketing copy and consent language drafted from the same fact set, reviewed by the same team, so a candidate reads consistent claims from the first ad impression through the signature line.
Comprehension, Health Literacy, and Who Gets Left Out
Comprehension has several axes under OHRP's 45 CFR 46.116 general requirements, and a consent form that clears an IRB's reading-level check on one axis can still exclude candidates a study needs to reach. Many IRBs ask drafters to target roughly an 8th-grade reading level for consent language, measured with a standard readability formula such as Flesch-Kincaid. That target lines up with the government's own health literacy research: the Agency for Healthcare Research and Quality's Health Literacy Universal Precautions Toolkit reports that the average US adult reads at only an 8th- to 9th-grade level, and that roughly one in five adults reads at a 5th-grade level or below. Hitting that reading level solves for one axis of comprehension and leaves several others untouched.
Language is the most obvious gap: a form translated only into English excludes any candidate whose primary language isn't English, regardless of how simply the English version is written. Format is another: a dense, single-column document is harder to parse than the same content broken into short sections with a heading before each one, even at an identical reading level. Delivery matters just as much as the document itself, since a candidate who receives the form five minutes before a signature deadline has functionally less comprehension time than one who receives it a week in advance, no matter how the sentences are written.
Comprehension is not one-size-fits-all: a rewrite at a 6th-grade reading level for one population can still exclude a candidate who needs the form in a different language, a gap addressed separately through outreach tactics that widen who a trial reaches. Consent language and recruitment outreach solve different halves of the same representativeness problem.
Before You Draft
Before you draft consent language for a live study, remember what this guide can and can't do for you. It shows composite, annotated examples of purpose, risk, and compensation language that reflect how IRBs actually apply 21 CFR 50.25 and 45 CFR 46.116. These examples are not a ready-to-sign form, and this guide is not a substitute for your own IRB's and legal counsel's review. The pattern that runs through all three annotated examples is the same: state the fact plainly, disclose the uncertainty honestly, and never let the phrasing do more persuasive work than the underlying data supports. That same discipline has to extend upstream into the recruitment ad, the landing page, and the intake call script, because a candidate who consents to one story and encounters a different one in the room is a candidate who declines, or worse, enrolls on a false premise.
Frequently Asked Questions
What are the required elements of informed consent?
Under 21 CFR 50.25, a compliant consent form has to state that the study is research, describe its purpose and procedures, disclose foreseeable risks and expected benefits, list alternative treatments, explain confidentiality protections, describe compensation for research-related injury when applicable, provide contact information for questions, and state that participation is voluntary and can be withdrawn at any time without penalty.
What does a good informed consent form look like?
A compliant consent form moves in a consistent order: plain-language purpose and procedures, then risks and benefits, then alternatives to participating, then compensation and costs, then a clear statement that participation is voluntary and withdrawal carries no penalty. The annotated purpose-and-procedures, risks-and-benefits, and compensation examples in this guide show that structure in full sentences rather than as a bare outline.
What is an example of an informed consent statement?
One compliant consent statement reads: "Taking part in this study is completely voluntary, and you may withdraw at any time without penalty or loss of benefits to which you are otherwise entitled." That single sentence satisfies the voluntary-participation element every consent form has to include under 21 CFR 50.25.
How do you write an informed consent form for a research study?
Start from your institution's approved template rather than a blank page, since most IRBs require a specific structure. Draft every section in plain language, following the rewrite pattern shown in this guide's annotated examples. Include every element 21 CFR 50.25 requires, from purpose through voluntary withdrawal. Then submit the draft to your IRB for review before it goes anywhere near a recruitment campaign.
Can a minor give informed consent?
Generally no: a minor gives assent, a simplified agreement to participate, while a parent or legal guardian provides informed permission on the minor's behalf. The exact age threshold and assent requirements vary by state and by the study's IRB, so pediatric consent language needs separate review outside the scope of this guide.
Does an informed consent form need IRB approval?
Yes: an Institutional Review Board has to review and approve the exact consent form language before a single participant can be enrolled. Most IRBs review recruitment materials, including ads, flyers, and landing pages, alongside the consent form itself, since inconsistent claims between the two are a common reason for a revise-and-resubmit.